Aldeyra resubmits topical ocular reproxalap NDA to FDA

Aldeyra (ALDX) announced the resubmission of a new drug application to the FDA for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new clinical data included in the resubmitted NDA were from the recently completed dry eye chamber trial, which achieved the primary endpoint.